Trovagene Inc (TROV) 4.39 $TROV
Trovagene Announces Presentation of Clinical Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Thu Dec 04, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that clinical data will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 6-9, 2014 at the Moscone Center in San Francisco. The clinical data highlight the use of Trovagene's Precision Cancer MonitoringSM technology for the determination of mutational status and longitudinal monitoring of disease dynamics from both urine and plasma cell-free DNA, and will be presented by David Hyman, M.D., Memorial Sloan-Kettering Cancer Center.
TROV: 4.39 (unch)
Trovagene to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference.
TROV: 4.39 (unch)
TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 4:35PM CST
TrovaGene, Inc. (TROV) recently unveiled clinical study results that reflect the capability of its Precision Cancer Monitoring technology in detecting and monitoring KRAS mutation in circulating tumor DNA (ctDNA).
TROV: 4.39 (unch), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients
PR Newswire - Thu Nov 20, 8:08AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today clinical study results highlighting the Company's ability to detect and quantitate KRAS mutations in blood and urine samples from patients with advanced colorectal cancer. The data, generated using Trovagene's Precision Cancer Monitoring technology, show that quantitative changes of mutational signals in blood and urine are highly correlated and further establish the clinical applicability of a simple urine sample for cancer monitoring. The clinical study was conducted in collaboration with Genomac International, a cancer genomic research center based in Prague, Czech Republic. Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D., presented the study results at the EORTC-NCI-AACR International Symposium on Molecular Targets and Therapeutics Meeting in Barcelona, Spain.
TROV: 4.39 (unch)
Trovagene to Present at Upcoming Healthcare Conferences
PR Newswire - Wed Nov 12, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.
TROV: 4.39 (unch)
TrovaGene's (TROV) CEO Antonius Schuh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:34PM CST
TROV: 4.39 (unch)
TrovaGene misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:04PM CST
TROV: 4.39 (unch)
Trovagene, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2014.
TROV: 4.39 (unch)
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 10.64 (+0.42), TROV: 4.39 (unch), PTCT: 55.87 (+0.54), HSIC: 133.80 (-1.20)
Trovagene Schedules Release of Third Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Oct 29, 7:10AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the third quarter and the nine months ended September 30, 2014 on Thursday, November 6, 2014 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
TROV: 4.39 (unch)
Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery
PR Newswire - Mon Oct 27, 7:10AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, today announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Study investigator Eli L. Diamond, M.D., a neuro-oncologist at Memorial Sloan Kettering Cancer Center, will present the clinical results at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.
TROV: 4.39 (unch)
Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.39 (unch)
Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.39 (unch)
Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.39 (unch)
Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.39 (unch)
Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.39 (unch)
How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.39 (unch)
TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 65.00 (-0.08), CBM: 23.66 (+0.24), TROV: 4.39 (unch), GILD: 104.13 (-0.18)
Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.39 (unch)
Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.39 (unch)
Trovagene Announces Presentation of Clinical Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Thu Dec 04, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that clinical data will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 6-9, 2014 at the Moscone Center in San Francisco. The clinical data highlight the use of Trovagene's Precision Cancer MonitoringSM technology for the determination of mutational status and longitudinal monitoring of disease dynamics from both urine and plasma cell-free DNA, and will be presented by David Hyman, M.D., Memorial Sloan-Kettering Cancer Center.
TROV: 4.39 (unch)
Trovagene to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference.
TROV: 4.39 (unch)
TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 4:35PM CST
TrovaGene, Inc. (TROV) recently unveiled clinical study results that reflect the capability of its Precision Cancer Monitoring technology in detecting and monitoring KRAS mutation in circulating tumor DNA (ctDNA).
TROV: 4.39 (unch), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients
PR Newswire - Thu Nov 20, 8:08AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today clinical study results highlighting the Company's ability to detect and quantitate KRAS mutations in blood and urine samples from patients with advanced colorectal cancer. The data, generated using Trovagene's Precision Cancer Monitoring technology, show that quantitative changes of mutational signals in blood and urine are highly correlated and further establish the clinical applicability of a simple urine sample for cancer monitoring. The clinical study was conducted in collaboration with Genomac International, a cancer genomic research center based in Prague, Czech Republic. Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D., presented the study results at the EORTC-NCI-AACR International Symposium on Molecular Targets and Therapeutics Meeting in Barcelona, Spain.
TROV: 4.39 (unch)
Trovagene to Present at Upcoming Healthcare Conferences
PR Newswire - Wed Nov 12, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.
TROV: 4.39 (unch)
TrovaGene's (TROV) CEO Antonius Schuh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:34PM CST
TROV: 4.39 (unch)
TrovaGene misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:04PM CST
TROV: 4.39 (unch)
Trovagene, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2014.
TROV: 4.39 (unch)
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 10.64 (+0.42), TROV: 4.39 (unch), PTCT: 55.87 (+0.54), HSIC: 133.80 (-1.20)
Trovagene Schedules Release of Third Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Oct 29, 7:10AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the third quarter and the nine months ended September 30, 2014 on Thursday, November 6, 2014 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
TROV: 4.39 (unch)
Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery
PR Newswire - Mon Oct 27, 7:10AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, today announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Study investigator Eli L. Diamond, M.D., a neuro-oncologist at Memorial Sloan Kettering Cancer Center, will present the clinical results at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.
TROV: 4.39 (unch)
Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.39 (unch)
Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.39 (unch)
Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.39 (unch)
Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.39 (unch)
Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.39 (unch)
How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.39 (unch)
TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 65.00 (-0.08), CBM: 23.66 (+0.24), TROV: 4.39 (unch), GILD: 104.13 (-0.18)
Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.39 (unch)
Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.39 (unch)
